Greenleaf Trust Invests $224,000 in Bio-Rad Laboratories, Inc. (NYSE:BIO)

Greenleaf Trust acquired a new position in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) in the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor acquired 695 shares of the medical research company’s stock, valued at approximately $224,000.

Other institutional investors and hedge funds have also made changes to their positions in the company. ING Groep NV acquired a new stake in shares of Bio-Rad Laboratories during the 3rd quarter worth $44,000. Banque Cantonale Vaudoise increased its holdings in shares of Bio-Rad Laboratories by 25.0% during the 3rd quarter. Banque Cantonale Vaudoise now owns 375 shares of the medical research company’s stock worth $135,000 after buying an additional 75 shares during the last quarter. First Eagle Investment Management LLC boosted its position in Bio-Rad Laboratories by 139.8% during the 3rd quarter. First Eagle Investment Management LLC now owns 458 shares of the medical research company’s stock worth $164,000 after purchasing an additional 267 shares during the period. Blue Trust Inc. boosted its position in Bio-Rad Laboratories by 42.0% during the 4th quarter. Blue Trust Inc. now owns 480 shares of the medical research company’s stock worth $172,000 after purchasing an additional 142 shares during the period. Finally, FDx Advisors Inc. purchased a new stake in Bio-Rad Laboratories during the 3rd quarter worth $214,000. 65.24% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on the stock. UBS Group upped their price target on shares of Bio-Rad Laboratories from $395.00 to $420.00 and gave the stock a “buy” rating in a research report on Friday, February 16th. Citigroup cut shares of Bio-Rad Laboratories from a “buy” rating to a “neutral” rating and decreased their price objective for the company from $400.00 to $365.00 in a research report on Wednesday, April 3rd. Royal Bank of Canada decreased their price objective on shares of Bio-Rad Laboratories from $484.00 to $480.00 and set an “outperform” rating for the company in a research report on Friday, February 16th. Finally, StockNews.com cut shares of Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a research report on Friday, April 5th. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $468.00.

Insider Activity

In related news, EVP Michael Crowley sold 3,000 shares of the stock in a transaction dated Tuesday, February 27th. The shares were sold at an average price of $336.00, for a total transaction of $1,008,000.00. Following the sale, the executive vice president now owns 6,942 shares in the company, valued at $2,332,512. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Company insiders own 17.50% of the company’s stock.

Bio-Rad Laboratories Stock Performance

Shares of Bio-Rad Laboratories stock opened at $278.04 on Thursday. The firm has a market cap of $7.93 billion, a PE ratio of -12.94 and a beta of 0.87. The firm’s 50-day simple moving average is $327.31 and its 200-day simple moving average is $318.45. The company has a debt-to-equity ratio of 0.14, a quick ratio of 4.34 and a current ratio of 5.83. Bio-Rad Laboratories, Inc. has a 1 year low of $261.59 and a 1 year high of $473.50.

Bio-Rad Laboratories (NYSE:BIO) last issued its earnings results on Thursday, February 15th. The medical research company reported $3.10 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.93 by $0.17. The business had revenue of $681.18 million for the quarter, compared to analyst estimates of $685.00 million. Bio-Rad Laboratories had a negative net margin of 23.86% and a positive return on equity of 3.90%. The company’s revenue for the quarter was down 6.7% on a year-over-year basis. During the same quarter in the prior year, the business posted $3.31 EPS. Equities analysts forecast that Bio-Rad Laboratories, Inc. will post 10.41 earnings per share for the current fiscal year.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.